Paxmedica announces publication of its autism spectrum disorder phase 2 study results in peer-reviewed journal

Tarrytown, ny / accesswire / november 7, 2023 / paxmedica, inc. (nasdaq:pxmd), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced the publication of research findings in the annals of general psychiatry. the research, led by chief medical officer dr. david hough, along with a team of renowned co-authors specializing in autism spectrum disorder (asd), the research explores the potential of low-dose suramin intravenous infusions as an asd treatment.
PXMD Ratings Summary
PXMD Quant Ranking